Zealand Pharma Outlines Metabolic Frontier 2030 Goal of Five Marketed Products at Morgan Stanley Conference, Anchored on Petrelintide
Zealand Pharma CEO Adam Steensberg spoke on Wednesday, September 16, 2026 at the Morgan Stanley 24th Annual Global Healthcare Conference, where he described the company's Metabolic Frontier 2030 ambition, launched the previous December: five products on the market and 10 clinical programs by 2030. He said petrelintide, Zealand's long-acting amylin analog, produced double-digit weight loss with placebo-like tolerability in the Phase 2 ZUPREME-1 trial and is moving into Phase 3 with Roche. Under the agreement the companies announced on March 12, 2025, Roche paid $1.65 billion upfront, the deal's total potential value is up to $5.3 billion, and profits on petrelintide and the petrelintide/CT-388 combination are shared 50/50 in the U.S. and Europe. Steensberg also discussed survodutide, partnered with Boehringer Ingelheim, and glepaglutide for short bowel syndrome.